Antibodies targeting immunoglobulin E Cε2 region as potential rapid anti-allergy therapy
Researchers identify novel Fab antibody fragments that remove mast cell-bound IgE, enabling faster treatment of severe allergic diseases
2026-01-26
(Press-News.org)
Allergic diseases represent a major global health burden, placing significant strain on healthcare systems worldwide. Severe conditions such as anaphylaxis, asthma, food allergy, and allergic rhinitis are driven by immunoglobulin E (IgE), an antibody that binds to immune cells including mast cells and basophils. When IgE remains attached to these cells, it sustains exaggerated immune responses to allergens. Although current anti-allergy therapies can neutralize free IgE in the bloodstream, they cannot efficiently remove IgE already bound to immune cells, delaying the onset of clinical benefit.
IgE contains a unique immunoglobulin-like domain, Cε2, which stabilizes its interaction with the high-affinity receptor FcεRI that anchors IgE to the surface of mast cells and basophils. In a recent study published in The Journal of Allergy and Clinical Immunology on December 11, 2025, researchers led by Associate Professor Tomoaki Ando and Professor Jiro Kitaura at Juntendo University Graduate School of Medicine, in collaboration with Toshiaki Maruyama of Abwiz Bio Inc., identified Fab (fragment antigen-binding) antibody fragments that target the IgE Cε2 domain and disrupt the IgE–FcεRI complex, effectively stripping IgE from mast cells.
“Previous studies in mice suggested that targeting the Cε2 domain could suppress IgE-dependent mast cell activation, yet whether this strategy could be applied to human IgE remained unclear due to substantial species differences between human and murine IgE. This gap in knowledge prompted us to ask whether the human IgE Cε2 domain could be exploited as a novel therapeutic target to destabilize IgE–receptor interactions,” explains Dr. Ando.
To systematically investigate antibodies against the human IgE Cε2 domain, the researchers generated Fab antibody libraries from immunized rabbits and screened them for activity against pre-formed IgE–FcεRI complexes. This approach revealed marked differences among Fab clones in their ability to destabilize IgE–receptor interactions. The most potent Fab fragments efficiently removed IgE already bound to mast cell surface receptors.
The team further evaluated whether these Fab antibody fragments could suppress IgE-driven allergic reactions in FcεRI-humanized mouse models. Their experiments showed that the most effective Fab clones significantly reduced allergic responses and inflammation in vivo, demonstrating both cellular and physiological efficacy.
“The study demonstrates, for the first time, that the Cε2 domain of human IgE is a viable therapeutic target, and identifies multiple antibody fragments that show rapid efficacy in cellular assays and in vivo anaphylaxis models,” explains Dr. Ando. “The most immediate real-world application of our findings is the development of a next-generation antibody therapy for allergic diseases that require rapid and reliable symptom control. In addition, this strategy could be applied in clinical settings where temporary but rapid desensitization is needed, such as before allergen exposure during immunotherapy or medical procedures,” he adds.
IgE circulates at low levels in human serum, enabling efficient neutralization of free IgE by existing therapies. However, their inability to remove IgE already bound to mast cells has remained a key limitation in achieving rapid symptom control. Antibody-based strategies targeting the human Cε2 domain may help overcome this challenge by directly destabilizing IgE–receptor complexes, although further studies will be required to confirm their clinical safety and efficacy.
Reference
Authors
Hexing Wang1,2, Tomoaki Ando1, Toshiaki Maruyama3, Shigeru CJ Okumura3, Kumi Izawa1, Ayako Kaitani1, Akie Maehara1, Risa Yamamoto1, Paul D Entzminger3, Jonathan K Fleming3, Nobuhiro Nakano1, Keiko Maeda1, Hideo Yagita4, Hideoki Ogawa1, Ko Okumura1, and Jiro Kitaura2
Title of original paper
Fabs targeting a Cε2 epitope disassemble IgE-receptor complexes and suppress anaphylaxis
Journal
The Journal of Allergy and Clinical Immunology
DOI
10.1016/j.jaci.2025.11.010
Affiliations
1Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, Japan
2Department of Science of Allergy and Inflammation, Juntendo University Graduate School of Medicine, Japan
3Abwiz Bio, Inc., San Diego, U.S.A.
4Department of Immunology, Juntendo University Graduate School of Medicine, Japan
About Associate Professor Tomoaki Ando
Dr. Tomoaki Ando is an Associate Professor at the Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine in Tokyo, Japan. He holds both an MD and a PhD from the University of Tokyo. His research spans pediatrics, allergology, and immunology, focusing on the cellular and molecular mechanisms underlying allergic disease. Dr. Ando studies mast cell biology, IgE-mediated allergic responses, allergen cross-reactivity, and inflammatory pathways, aiming to translate fundamental immunological insights into innovative therapeutic strategies for allergic and inflammatory disorders. His work bridges basic science with relevant translational applications.
END
ELSE PRESS RELEASES FROM THIS DATE:
2026-01-26
An experiment in western China over the past four decades shows that it is possible to tame the expansion of desert lands with greenery, and, in the process, pull excess carbon dioxide out of the sky.
The sprawling greening project along the edges of China’s Taklamakan Desert is creating a visible and measurable carbon sink, even in one of the driest places on Earth, according to a study led by scientists at the University of California, Riverside. The project is an example of successful afforestation, which is an effort to plant trees or shrubs on previously ...
2026-01-26
Americans born in the 1960s and early 1970s report higher loneliness and depressive symptoms and show poorer memory and physical strength than earlier generations. Such declines are largely absent in peer countries, particularly in Nordic Europe, where outcomes have improved over time.
In a new study, psychologist Frank J. Infurna of Arizona State University and co-authors, analyzed survey data from 17 countries seeking to identify why U.S. trends diverge from other wealthy nations.
“The real midlife crisis ...
2026-01-26
Research Highlights:
A study in France found that if sodium reduction targets focused on reducing salt in baguettes and other breads, they could lower daily salt intake by 0.35 grams per person and reduce national deaths by more than 1,000.
A similar study in the United Kingdom found that if 2024 salt reduction goals in that country could lower daily salt intake by 17.5%, potentially preventing about 100,000 cases of ischemic heart disease and 25,000 ischemic strokes over 20 years through reduced blood pressure.
Both studies reinforce the importance of coordinated efforts among policymakers, the food industry and others to strengthen and enforce ...
2026-01-26
Researchers at all career stages, as well as institutions and initiatives, are invited to apply or nominate candidates for the prestigious international €350,000 Einstein Foundation Award – the only prize dedicated to honoring outstanding contributions to strengthening the rigor, reliability, robustness, and transparency of research across the humanities, social sciences, natural sciences, and life sciences.
The submission deadline is April 30, 2026, with winners to be announced at the end of the year.
The ...
2026-01-26
Northwestern University researchers have developed the first device that can continuously track a fetus’s vital signs while still in the uterus — a feat that previously has not been possible.
The soft, flexible, robotic probe could dramatically improve safety during fetal surgeries, procedures in which physicians operate on a fetus before birth. Currently, doctors primarily rely on intermittent measurements of fetal heart rate using ultrasound imaging from outside the pregnant person’s body. The new device, on the other hand, can be gently inserted through the same ...
2026-01-26
Seoul, South Korea (January 26, 2026)—MDPI, the open access publisher, has appointed Sangwoo Lee as head of its South Korea office. Mr. Lee joins from Public Relations agency Prain Global, where he served for more than three years as chief director of strategic communications consulting institute. In his new role, Mr. Lee will lead MDPI’s operations in South Korea and oversee marketing, communications, and external affairs.
Mr. Lee brings more than 20 years of experience in communications (public affairs, crisis management, public policy, and public relations), including senior roles at Synergy Hill and Knowlton (now Synergy Burson) and Macoll Consulting Group. His ...
2026-01-26
Studies have demonstrated a link between alcohol consumption and an elevated risk of colorectal cancer. New research now reveals that higher lifetime alcohol consumption is also associated with a higher risk, especially for rectal cancer, and that quitting drinking can lower a person’s risk. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
When investigators analyzed data on US adults enrolled in the National Cancer Institute (NCI) Prostate, ...
2026-01-26
At the United Nations Climate Change Conference in 2015, countries around the world committed to striving towards net-zero greenhouse gas emissions by the middle of the 21st century. But achieving this goal is difficult, even for countries boasting extensive forests that could, in principle, act as important carbon sinks if deforestation were halted.
Now, a study in Frontiers in Forests and Global Change has shown that in Peru, national forest regulations will need a substantial review if the country is to meet its goal of achieving net-zero by 2050. In particular, ...
2026-01-26
COVID-19 brought about lasting changes that are still being felt today in the post-pandemic era, with one being the unprecedented side effect known as Long COVID.
Long COVID is characterized by symptoms affecting multiple organs and persisting for at least three months or longer after a COVID-19 infection. It has often been reported to be associated with advanced age, being female, obesity, and having other underlying conditions. However, there has not been a clear conclusion in its relation to smoking.
A ...
2026-01-26
Eating a plant-forward diet and limiting added sugars and fats as part of the EAT–Lancet planetary diet was associated with a reduced risk of chronic kidney disease (CKD), according to a large study published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250457.
Chronic kidney disease affects about 10% of adults globally and is projected to become the fifth leading cause of death worldwide by 2040.
The study was based on data from the UK Biobank, a large-scale long-term study that included 179 508 eligible participants aged 40 to 69 from England, Scotland and Wales, and dietary ...
LAST 30 PRESS RELEASES:
[Press-News.org] Antibodies targeting immunoglobulin E Cε2 region as potential rapid anti-allergy therapy
Researchers identify novel Fab antibody fragments that remove mast cell-bound IgE, enabling faster treatment of severe allergic diseases
